CA3046350C - Glyceryl 3-hydroxybutyrates for migraine symptom management - Google Patents

Glyceryl 3-hydroxybutyrates for migraine symptom management Download PDF

Info

Publication number
CA3046350C
CA3046350C CA3046350A CA3046350A CA3046350C CA 3046350 C CA3046350 C CA 3046350C CA 3046350 A CA3046350 A CA 3046350A CA 3046350 A CA3046350 A CA 3046350A CA 3046350 C CA3046350 C CA 3046350C
Authority
CA
Canada
Prior art keywords
mivi
hydroxybutyrate
glyceryl
migraine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3046350A
Other languages
English (en)
French (fr)
Other versions
CA3046350A1 (en
Inventor
Sami HASHIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuroenergy Ventures Inc
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of CA3046350A1 publication Critical patent/CA3046350A1/en
Application granted granted Critical
Publication of CA3046350C publication Critical patent/CA3046350C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3046350A 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management Active CA3046350C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/389,828 US20180177753A1 (en) 2016-12-23 2016-12-23 Glyceryl 3-hydroxybutyrates for migraine symptom management
US15/389,828 2016-12-23
PCT/US2017/063832 WO2018118369A1 (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Publications (2)

Publication Number Publication Date
CA3046350A1 CA3046350A1 (en) 2018-06-28
CA3046350C true CA3046350C (en) 2022-08-16

Family

ID=62624821

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3046350A Active CA3046350C (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Country Status (13)

Country Link
US (2) US20180177753A1 (enExample)
EP (1) EP3558458B1 (enExample)
JP (1) JP7108320B2 (enExample)
KR (1) KR102390608B1 (enExample)
CN (1) CN110167637B (enExample)
BR (1) BR112019012431A2 (enExample)
CA (1) CA3046350C (enExample)
ES (1) ES2962879T3 (enExample)
IL (1) IL267540B (enExample)
MX (1) MX389468B (enExample)
MY (1) MY190308A (enExample)
PT (1) PT3558458T (enExample)
WO (1) WO2018118369A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
WO2018115158A1 (en) 2016-12-21 2018-06-28 Universitäts-Kinderspital Beider Basel Migraine prevention and treatment
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
ES2965646T3 (es) * 2019-01-17 2024-04-16 Ketolipix Therapeutics Gmbh Procedimiento para la producción de lípidos que contienen unidades estructurales a base de glicéridos de ácidos hidroxicarboxílicos
WO2020147978A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von glyceriden von hydroxycarbonsäuren
IL278422B (en) * 2019-03-14 2022-09-01 Neuroenergy Ventures Inc A flavor masking formulation for ketone body compounds
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
CN113710243A (zh) * 2019-05-30 2021-11-26 神经活力投资公司 甘油三(β-羟基丁酸酯)与神经元短暂性脑缺血发作
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
AU2022387742A1 (en) * 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
WO2023094654A1 (en) 2021-11-26 2023-06-01 Arxada Ag Acetoacetate based ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
US12622967B2 (en) * 2022-01-18 2026-05-12 Today, Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
EP4605371A1 (en) 2022-10-18 2025-08-27 Arxada AG Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
AU2010207597A1 (en) * 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) * 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
SG11201809211QA (en) 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
JP2019526607A (ja) 2016-09-12 2019-09-19 ユニバーシティ・オブ・サウス・フロリダ ケトンにより改善された神経再生
WO2018115158A1 (en) 2016-12-21 2018-06-28 Universitäts-Kinderspital Beider Basel Migraine prevention and treatment

Also Published As

Publication number Publication date
MX2019006844A (es) 2019-08-16
BR112019012431A2 (pt) 2020-04-14
IL267540A (en) 2019-08-29
US20190117612A1 (en) 2019-04-25
CA3046350A1 (en) 2018-06-28
CN110167637B (zh) 2023-03-14
MX389468B (es) 2025-03-20
JP2020502250A (ja) 2020-01-23
PT3558458T (pt) 2023-11-27
US20180177753A1 (en) 2018-06-28
EP3558458A1 (en) 2019-10-30
EP3558458B1 (en) 2023-10-18
KR102390608B1 (ko) 2022-04-25
MY190308A (en) 2022-04-13
KR20190099465A (ko) 2019-08-27
CN110167637A (zh) 2019-08-23
JP7108320B2 (ja) 2022-07-28
US10792269B2 (en) 2020-10-06
IL267540B (en) 2022-07-01
WO2018118369A1 (en) 2018-06-28
EP3558458A4 (en) 2020-08-12
ES2962879T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
US10792269B2 (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
US11638702B2 (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
EP0637957B1 (de) Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
CN103458893B (zh) Sn‑1(3)单酰基甘油酯和脂质吸收
US20070259037A1 (en) Method and composition for treatment of inflammatory conditions
AU2012235869B2 (en) Compositions for the treatment of neurologic disorders
JP4986321B2 (ja) 炎症性状態処置のための方法および組成物
JP6378629B2 (ja) 酸化ストレスの低減におけるｄｈａ及びｅｐａ
JPH06172169A (ja) 脂肪酸治療
CN116490181A (zh) 在人中施用β-羟基丁酸和相关化合物用于治疗和/或预防呼吸道疾病
HK40012930B (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
HK40012930A (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
CHOW Role of vitamins in lipid metabolism
US6927239B1 (en) Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
EP1147769A2 (de) Verwendung von mehrfach ungesättigten Fettsäuren, insbesondere Omega-3-Fettsäuren, zur Behandlung von Enuresis und Inkontinenz
WO2002009692A1 (en) Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
HK40012461A (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210902

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241118

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241118

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251126

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251126